Post by K&L Gates

We recently advised StemCyte, a leading provider of cord blood banking and stem cell-related services, on its US$14 million initial public offering on the Taiwan Stock Exchange. The Corporate team was led by Taipei partners Cheryl Hsieh and Billy Chen, with support from Palo Alto partner K. Kevin Cao. Learn more here: https://ow.ly/ZbuZ50Ze3WW